Michelle M Cloutier, MD, is professor emerita at UCONN Health in Farmington, Connecticut, and chair of the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group.
Michelle M. Cloutier, MD, is professor emerita at UCONN Health in Farmington, Connecticut, and chair of the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group. Cloutier will present "2020 Focused Updates to the Asthma Management Guidelines: Report from the U.S. NAEPPCC Expert Panel Working Group," at this year's American Thoracic Society (ATS) annual conference.
Transcript
Can you introduce yourself and preview the talk on Updates to Asthma Management Guidelines you will give at ATS 2021?
I'm Dr. Michelle Cloutier. I'm a pediatric pulmonologist, and I am an emerita professor of pediatrics and medicine at UCONN Health in Farmington, Connecticut.
The NAEPP Coordinating Committee decided several years ago to update the asthma guidelines, the last update having been released in 2007. They, along with another working group, determined 6 topics for updating. In July of 2018, the NAEPP Coordinating Committee convened a group of individuals, both asthma content experts as well as primary care clinicians, and health care policy dissemination and implementation people, to update the guidelines in these 6 focused topics. These guidelines were subsequently released in December of 2020.
Our talk on this at the American Thoracic Society meeting is to present, briefly, the 19 recommendations that emerged from this expert panel on these 6 focused topics.
What are you most looking forward to at the meeting?
I think it's really important for both the asthma specialty community as well as the asthma primary care community to understand these new recommendations, to understand how to incorporate these new recommendations into their practice, and to help them with making decisions with their patients regarding what kinds of therapies to implement in their particular patient population and in individuals themselves.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More